Takeda CEO Julie Kim proposes $1.62M share sale
The notice lists acquisition of 190,406 ADSs through restricted stock unit awards that vested on July 1, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Takeda Pharmaceutical Company Limited (TAK) President and CEO Julie Kim reported 96,558 American Depositary Shares (ADSs) for sale, with an approximate sale date of July 13, 2026. The notice gives an aggregate market value of $1,617,344.29 and identifies Interactive Brokers LLC as broker. It lists 190,406 ADSs acquired from Takeda through restricted stock unit awards that vested on July 1, 2026.
Filing Explained
The filing shows a proposed, not completed, 190,406-ADS sale tied to vested RSU awards, with no issuer issuance disclosed.
The
The securities are identified as acquired through vested restricted stock unit awards and are listed for sale through Interactive Brokers LLC.
Because the filing is a proposed-sale notice, it does not establish that the ADSs were sold or that existing common holders were diluted.
The supplied filing does not disclose a trading plan, so it does not support classifying the proposed sale as plan-based.
Key Figures
Key Terms
Restricted Stock Unit Awards - Vested financial
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many TAK ADSs did Julie Kim report for sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.